Otonomy Reports Corporate and Product Pipeline Update
06 janv. 2022 07h51 HE
|
Otonomy, Inc.
Multiple clinical trial readouts for OTO-313 in tinnitus and OTO-413 in hearing loss expected during 2022 Current capital funds operations into second half of 2023 SAN DIEGO, Jan. 06, 2022 (GLOBE...
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
03 janv. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
16 nov. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
10 nov. 2021 16h18 HE
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter...
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
03 nov. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
27 oct. 2021 07h30 HE
|
Otonomy, Inc.
Presentation of positive top-line clinical results for OTO-313 in tinnitus and OTO-413 in hearing loss Supportive preclinical data to be presented for OTO-825 gene therapy and OTO-510 otoprotection...
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
12 oct. 2021 07h30 HE
|
Otonomy, Inc.
Results published in Otology & Neurotology, a leading journal in fieldOTO-313 was well-tolerated and demonstrated a statistically significant higher proportion of responders than placebo across...
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting
27 sept. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Participate in Two Upcoming Investor Conferences
02 sept. 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Appoints Jill Broadfoot to Board of Directors
19 août 2021 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...